uMotif to Showcase Modern eConsent and eCOA Platform to Bolster the Pivotal Patient-Site Relationship in Clinical Trials at Life Sciences Events

CEO Andrea Valente, Chief Design Officer Ben James, Chief Scientific Officer Florence Mowlem PhD, Chief Commercial Officer James Thatcher to highlight how uMotif delivers consumer-grade technology for participants and sites, enabling sponsors to run smarter, faster trials

BOSTON MA and London UK – September 10, 2026 – uMotif – one of the fastest-growing companies in the clinical trial technology market – kicks off the life sciences industry’s fall conference season with a continued call to put the research patient first.

The uMotif team will share insights and best practices for supporting patients and their connections to sites at 12 conferences and symposia including therapeutic-specific forums focused on Epilepsy, Oncology, and Obesity.

uMotif enters the conference season on the heels of several major developments for the company. In the first half of 2026, uMotif named Andrea Valente, who joined the company as Chief Operating Officer, to the position of Chief Executive Officer; appointed industry veteran sales executive James Thatcher as Chief Commercial Officer, and launched Scientific Consulting Services under the leadership of Chief Scientific Officer Florence Mowlem PhD, who won the 2026 PCMG Outsourcing Trailblazer of the Year Award.

To arrange a meeting with a uMotif executive at any of the following events, [email protected].

September

• SCDM 2026 Annual Conference, September 14-17, Raleigh Convention Center, Raleigh NC
• DPHARM, September 15-16, Sheraton Boston Hotel, Boston MA
• OCT Southern California, September 15-16, Hyatt Regency La Jolla at Aventine, San Diego CA

November 

• CNS Summit, November 1-4, Encore Boston Harbor, Boston MA 
• OCT DACH, November 3-4, Congress Center Basel, in Basel, Switzerland 
• Obesity Week, November 14-17, Gaylord National Resort & Convention Center, National Harbor MD  

December 

• American Epilepsy Society Annual Meeting, Colorado Convention Center, December 4-8, Denver CO 

About uMotif
Putting patients first is in uMotif’s DNA. The modern uMotif eCOA platform delivers faster, high-quality clinical trials and real-world studies by putting patients at the core of research. Combined with uMotif’s robust site tools – including consent management, site productivity, and trial awareness – the platform strengthens the patient-site relationship, which is key to improving eCOA compliance and retention. With cloud hosting in the US, Europe, and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports all study phases and indications. Visit www.umotif.com